- Home
- CHEC vs MOLN Comparison
CHEC vs MOLN Comparison
Compare CHEC & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Company Overview
Basic Information| Metric | CHEC | MOLN |
|---|---|---|
| Founded | 2024 | 2004 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.5M | 170.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHEC | MOLN |
|---|---|---|
| Price | $10.23 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 6.5K | 972.0 |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.91 | $3.53 |
| 52 Week High | $10.56 | $5.36 |
Technical Indicators
Market Signals| Indicator | CHEC | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 53.74 |
| Support Level | $10.15 | $4.13 |
| Resistance Level | $10.47 | $4.51 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.50 | 46.67 |
Price Performance
Historical Comparison CHEC
MOLN
About CHEC Chenghe Acquisition III Co. Class A Ordinary Share
Chenghe Acquisition III Co is blank check company.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.